APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immune Checkpoint Inhibitors for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Immune Checkpoint Inhibitors for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025189 pages

Choose your research edition.

Industry ResearchImmune Checkpoint Inhibitors for Cancer Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Immune Checkpoint Inhibitors for Cancer Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Immune Checkpoint Inhibitors for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immune Checkpoint Inhibitors for Cancer Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Immune Checkpoint Inhibitors for Cancer Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Immune Checkpoint Inhibitors for Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Immune Checkpoint Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immune Checkpoint Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immune Checkpoint Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Immune Checkpoint Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Immune Checkpoint Inhibitors for Cancer include Innovent Biologics, Merck, Roche, Pfizer, Zydus, Regeneron Pharmaceuticals, Bristol Myers Squibb and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Immune Checkpoint Inhibitors for Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immune Checkpoint Inhibitors for Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immune Checkpoint Inhibitors for Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Immune Checkpoint Inhibitors for Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.

Immune Checkpoint Inhibitors for Cancer Segment by Company

Innovent Biologics

Merck

Roche

Pfizer

Zydus

Regeneron Pharmaceuticals

Bristol Myers Squibb

AstraZeneca

Immune Checkpoint Inhibitors for Cancer Segment by Type

CTLA-4 Inhibitors

PD-1 Inhibitors

PD-L1 Inhibitors

Immune Checkpoint Inhibitors for Cancer Segment by Application

Gastric Cancer

Squamous Cell Skin Cancer

Melanoma

Non-small Cell Lung Cancer

Others

Immune Checkpoint Inhibitors for Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Checkpoint Inhibitors for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immune Checkpoint Inhibitors for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Checkpoint Inhibitors for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Immune Checkpoint Inhibitors for Cancer market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Immune Checkpoint Inhibitors for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Immune Checkpoint Inhibitors for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Immune Checkpoint Inhibitors for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Immune Checkpoint Inhibitors for Cancer Industry Trends Table 2. Immune Checkpoint Inhibitors for Cancer Industry Drivers Table 3. Immune Checkpoint Inhibitors for Cancer Industry Opportunities and Challenges Table 4. Immune Checkpoint Inhibitors for Cancer Industry Restraints Table 5. Global Immune Checkpoint Inhibitors for Cancer Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Immune Checkpoint Inhibitors for Cancer Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Manufacturers Table 9. Global Immune Checkpoint Inhibitors for Cancer Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Immune Checkpoint Inhibitors for Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Immune Checkpoint Inhibitors for Cancer Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Immune Checkpoint Inhibitors for Cancer Manufacturers, Product Type & Application Table 13. Global Immune Checkpoint Inhibitors for Cancer Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Immune Checkpoint Inhibitors for Cancer by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of CTLA-4 Inhibitors Table 17. Major Manufacturers of PD-1 Inhibitors Table 18. Major Manufacturers of PD-L1 Inhibitors Table 19. Global Immune Checkpoint Inhibitors for Cancer Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 21. Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 22. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Type (2021-2026) Table 23. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Type (2027-2032) Table 24. Global Immune Checkpoint Inhibitors for Cancer Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Immune Checkpoint Inhibitors for Cancer Revenue by Type (2021-2026) & (K Units) Table 26. Global Immune Checkpoint Inhibitors for Cancer Revenue by Type (2027-2032) & (K Units) Table 27. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Type (2021-2026) Table 28. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Gastric Cancer Table 30. Major Manufacturers of Squamous Cell Skin Cancer Table 31. Major Manufacturers of Melanoma Table 32. Major Manufacturers of Non-small Cell Lung Cancer Table 33. Major Manufacturers of Others Table 34. Global Immune Checkpoint Inhibitors for Cancer Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 36. Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 37. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Application (2021-2026) Table 38. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Application (2027-2032) Table 39. Global Immune Checkpoint Inhibitors for Cancer Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Immune Checkpoint Inhibitors for Cancer Revenue by Application (2021-2026) & (K Units) Table 41. Global Immune Checkpoint Inhibitors for Cancer Revenue by Application (2027-2032) & (K Units) Table 42. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Application (2021-2026) Table 43. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Application (2027-2032) Table 44. Global Immune Checkpoint Inhibitors for Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Immune Checkpoint Inhibitors for Cancer Sales by Region (2021-2026) & (K Units) Table 46. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Region (2021-2026) Table 47. Global Immune Checkpoint Inhibitors for Cancer Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Immune Checkpoint Inhibitors for Cancer Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Immune Checkpoint Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 51. North America Immune Checkpoint Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 52. Europe Immune Checkpoint Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 54. Europe Immune Checkpoint Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 61. Global Immune Checkpoint Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Immune Checkpoint Inhibitors for Cancer Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Immune Checkpoint Inhibitors for Cancer Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Region (2021-2026) Table 65. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Region (2027-2032) Table 66. Innovent Biologics Company Information Table 67. Innovent Biologics Business Overview Table 68. Innovent Biologics Immune Checkpoint Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Innovent Biologics Immune Checkpoint Inhibitors for Cancer Product Portfolio Table 70. Innovent Biologics Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Immune Checkpoint Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Merck Immune Checkpoint Inhibitors for Cancer Product Portfolio Table 75. Merck Recent Development Table 76. Roche Company Information Table 77. Roche Business Overview Table 78. Roche Immune Checkpoint Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Roche Immune Checkpoint Inhibitors for Cancer Product Portfolio Table 80. Roche Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Immune Checkpoint Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Pfizer Immune Checkpoint Inhibitors for Cancer Product Portfolio Table 85. Pfizer Recent Development Table 86. Zydus Company Information Table 87. Zydus Business Overview Table 88. Zydus Immune Checkpoint Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Zydus Immune Checkpoint Inhibitors for Cancer Product Portfolio Table 90. Zydus Recent Development Table 91. Regeneron Pharmaceuticals Company Information Table 92. Regeneron Pharmaceuticals Business Overview Table 93. Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Product Portfolio Table 95. Regeneron Pharmaceuticals Recent Development Table 96. Bristol Myers Squibb Company Information Table 97. Bristol Myers Squibb Business Overview Table 98. Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Product Portfolio Table 100. Bristol Myers Squibb Recent Development Table 101. AstraZeneca Company Information Table 102. AstraZeneca Business Overview Table 103. AstraZeneca Immune Checkpoint Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. AstraZeneca Immune Checkpoint Inhibitors for Cancer Product Portfolio Table 105. AstraZeneca Recent Development Table 106. Key Raw Materials Table 107. Raw Materials Key Suppliers Table 108. Immune Checkpoint Inhibitors for Cancer Distributors List Table 109. Immune Checkpoint Inhibitors for Cancer Customers List Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Immune Checkpoint Inhibitors for Cancer Product Image Figure 2. Global Immune Checkpoint Inhibitors for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immune Checkpoint Inhibitors for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Immune Checkpoint Inhibitors for Cancer Sales (2021-2032) & (K Units) Figure 5. Global Immune Checkpoint Inhibitors for Cancer Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Immune Checkpoint Inhibitors for Cancer Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. CTLA-4 Inhibitors Image Figure 9. PD-1 Inhibitors Image Figure 10. PD-L1 Inhibitors Image Figure 11. Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Type (2021-2032) Figure 14. Global Immune Checkpoint Inhibitors for Cancer Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Type (2021-2032) Figure 17. Gastric Cancer Image Figure 18. Squamous Cell Skin Cancer Image Figure 19. Melanoma Image Figure 20. Non-small Cell Lung Cancer Image Figure 21. Others Image Figure 22. Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Application (2021-2032) Figure 25. Global Immune Checkpoint Inhibitors for Cancer Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Application (2021-2032) Figure 28. North America Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Immune Checkpoint Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 30. U.S. Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Immune Checkpoint Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 35. Germany Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 42. China Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 50. Brazil Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Immune Checkpoint Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Immune Checkpoint Inhibitors for Cancer Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Immune Checkpoint Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 61. North America Immune Checkpoint Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Immune Checkpoint Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 63. Europe Immune Checkpoint Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Immune Checkpoint Inhibitors for Cancer Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Immune Checkpoint Inhibitors for Cancer Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • CTLA-4 Inhibitors
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Gastric Cancer
  • Squamous Cell Skin Cancer
  • Melanoma
  • Non-small Cell Lung Cancer
  • Others
Companies covered
  • Innovent Biologics
  • Merck
  • Roche
  • Pfizer
  • Zydus
  • Regeneron Pharmaceuticals
  • Bristol Myers Squibb
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Immune Checkpoint Inhibitors for Cancer Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Immune Checkpoint Inhibitors for Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Immune Checkpoint Inhibitors for Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Immune Checkpoint Inhibitors for Cancer Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Immune Checkpoint Inhibitors for Cancer Market Dynamics
  1. 2.1 Immune Checkpoint Inhibitors for Cancer Industry Trends
  2. 2.2 Immune Checkpoint Inhibitors for Cancer Industry Drivers
  3. 2.3 Immune Checkpoint Inhibitors for Cancer Industry Opportunities and Challenges
  4. 2.4 Immune Checkpoint Inhibitors for Cancer Industry Restraints
3 Immune Checkpoint Inhibitors for Cancer Market by Manufacturers
  1. 3.1 Global Immune Checkpoint Inhibitors for Cancer Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Immune Checkpoint Inhibitors for Cancer Sales by Manufacturers (2021-2026)
  3. 3.3 Global Immune Checkpoint Inhibitors for Cancer Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Immune Checkpoint Inhibitors for Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Immune Checkpoint Inhibitors for Cancer Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Immune Checkpoint Inhibitors for Cancer Manufacturers, Product Type & Application
  7. 3.7 Global Immune Checkpoint Inhibitors for Cancer Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Immune Checkpoint Inhibitors for Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Immune Checkpoint Inhibitors for Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Immune Checkpoint Inhibitors for Cancer Tier 1, Tier 2, and Tier 3
4 Immune Checkpoint Inhibitors for Cancer Market by Type
  1. 4.1 Immune Checkpoint Inhibitors for Cancer Type Introduction
  2. 4.1.1 CTLA-4 Inhibitors
  3. 4.1.2 PD-1 Inhibitors
  4. 4.1.3 PD-L1 Inhibitors
  5. 4.2 Global Immune Checkpoint Inhibitors for Cancer Sales by Type
  6. 4.2.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2021-2032)
  8. 4.2.3 Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Type (2021-2032)
  9. 4.3 Global Immune Checkpoint Inhibitors for Cancer Revenue by Type
  10. 4.3.1 Global Immune Checkpoint Inhibitors for Cancer Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Immune Checkpoint Inhibitors for Cancer Revenue by Type (2021-2032)
  12. 4.3.3 Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Type (2021-2032)
5 Immune Checkpoint Inhibitors for Cancer Market by Application
  1. 5.1 Immune Checkpoint Inhibitors for Cancer Application Introduction
  2. 5.1.1 Gastric Cancer
  3. 5.1.2 Squamous Cell Skin Cancer
  4. 5.1.3 Melanoma
  5. 5.1.4 Non-small Cell Lung Cancer
  6. 5.1.5 Others
  7. 5.2 Global Immune Checkpoint Inhibitors for Cancer Sales by Application
  8. 5.2.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2021-2032)
  10. 5.2.3 Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Application (2021-2032)
  11. 5.3 Global Immune Checkpoint Inhibitors for Cancer Revenue by Application
  12. 5.3.1 Global Immune Checkpoint Inhibitors for Cancer Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Immune Checkpoint Inhibitors for Cancer Revenue by Application (2021-2032)
  14. 5.3.3 Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Application (2021-2032)
6 Global Immune Checkpoint Inhibitors for Cancer Sales by Region
  1. 6.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immune Checkpoint Inhibitors for Cancer Sales by Region (2021-2032)
  3. 6.2.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Region (2021-2026)
  4. 6.2.2 Global Immune Checkpoint Inhibitors for Cancer Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Immune Checkpoint Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Immune Checkpoint Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Immune Checkpoint Inhibitors for Cancer Revenue by Region
  1. 7.1 Global Immune Checkpoint Inhibitors for Cancer Revenue by Region
  2. 7.1.1 Global Immune Checkpoint Inhibitors for Cancer Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Immune Checkpoint Inhibitors for Cancer Revenue by Region (2021-2026)
  4. 7.1.3 Global Immune Checkpoint Inhibitors for Cancer Revenue by Region (2027-2032)
  5. 7.1.4 Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Immune Checkpoint Inhibitors for Cancer Revenue (2021-2032)
  8. 7.2.2 North America Immune Checkpoint Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Immune Checkpoint Inhibitors for Cancer Revenue (2021-2032)
  11. 7.3.2 Europe Immune Checkpoint Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Immune Checkpoint Inhibitors for Cancer Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Immune Checkpoint Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Innovent Biologics
  2. 8.1.1 Innovent Biologics Company Information
  3. 8.1.2 Innovent Biologics Business Overview
  4. 8.1.3 Innovent Biologics Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Innovent Biologics Immune Checkpoint Inhibitors for Cancer Product Portfolio
  6. 8.1.5 Innovent Biologics Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Immune Checkpoint Inhibitors for Cancer Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Immune Checkpoint Inhibitors for Cancer Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Immune Checkpoint Inhibitors for Cancer Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Zydus
  26. 8.5.1 Zydus Company Information
  27. 8.5.2 Zydus Business Overview
  28. 8.5.3 Zydus Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Zydus Immune Checkpoint Inhibitors for Cancer Product Portfolio
  30. 8.5.5 Zydus Recent Developments
  31. 8.6 Regeneron Pharmaceuticals
  32. 8.6.1 Regeneron Pharmaceuticals Company Information
  33. 8.6.2 Regeneron Pharmaceuticals Business Overview
  34. 8.6.3 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Product Portfolio
  36. 8.6.5 Regeneron Pharmaceuticals Recent Developments
  37. 8.7 Bristol Myers Squibb
  38. 8.7.1 Bristol Myers Squibb Company Information
  39. 8.7.2 Bristol Myers Squibb Business Overview
  40. 8.7.3 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Product Portfolio
  42. 8.7.5 Bristol Myers Squibb Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Immune Checkpoint Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Immune Checkpoint Inhibitors for Cancer Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Immune Checkpoint Inhibitors for Cancer Value Chain Analysis
  2. 9.1.1 Immune Checkpoint Inhibitors for Cancer Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Immune Checkpoint Inhibitors for Cancer Production Mode & Process
  6. 9.2 Immune Checkpoint Inhibitors for Cancer Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Immune Checkpoint Inhibitors for Cancer Distributors
  9. 9.2.3 Immune Checkpoint Inhibitors for Cancer Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst